	US 11,939,310 B2
	Polymerase inhibitors and related compositions and methods
Wenhui Zhou, Madison, WI (US); Kimberly K. Knoche, Madison, WI (US); Douglas R. Storts, Madison, WI (US); Min Zhou, Madison, WI (US); and Poncho Meisenheimer, Madison, WI (US)
Assigned to Promega Corporation, Madison, WI (US)
Filed by Promega Corporation, Madison, WI (US)
Filed on Oct. 25, 2022, as Appl. No. 18/049,517.
Application 18/049,517 is a division of application No. 16/712,098, filed on Dec. 12, 2019, granted, now 11,524,946.
Claims priority of provisional application 62/778,590, filed on Dec. 12, 2018.
Prior Publication US 2023/0097403 A1, Mar. 30, 2023
Int. Cl. C07D 307/42 (2006.01); C07C 317/28 (2006.01); C07D 307/80 (2006.01); C07D 311/58 (2006.01); C12N 9/12 (2006.01); C12P 19/34 (2006.01)

CPC C07D 307/42 (2013.01) [C07C 317/28 (2013.01); C07D 307/80 (2013.01); C07D 311/58 (2013.01); C12N 9/1252 (2013.01); C12P 19/34 (2013.01); C12Y 207/07007 (2013.01)]

16 Claims

1. A composition comprising a compound of formula (II):

or a salt thereof,

wherein:

A is selected from a monocyclic or bicyclic aryl, heteroaryl, or heterocyclyl group, each of which may be optionally substituted with 1, 2, or 3 substituents;

R¹is C₆-C₂₀alkyl;

R²is selected from hydrogen and —COOH;

n is 1 or 2; and

R³is selected from —COOH and —SO₃X, wherein X is selected from hydrogen, an alkali metal cation, and an ammonium cation; and

one or more nucleic acid amplification reagents.